Alnylam grants InterfeRx license to Sylentis
Both the companies will discover, develop and commercialize synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Once Sylentis exercises this option, Alnylam will be
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).